From: Blood consumption in total arterial coronary artery bypass grafting
Variable | Entire cohort N = 595 | Total arterial CABG N = 419 (70.4%) | Mixed CABG N = 176 (29.6%) | p value |
---|---|---|---|---|
Male | 501 (84.2%) | 360 (85.9%) | 141 (80.1%) | 0.08 |
Age (y) | 66.1 ± 9.5 | 66.0 ± 9.5 | 66.5 ± 9.5 | 0.55 |
< 60 | 139 (23.4%) | 100 (23.9%) | 39 (22.2%) | – |
60–69 | 230 (38.7%) | 167 (39.9%) | 63 (35.8%) | – |
70–79 | 186 (31.3%) | 124 (29.6%) | 62 (35.2%) | – |
≥ 80 | 40 (6.7%) | 28 (6.7%) | 12 (6.8%) | – |
Diabetes | 162 (27.2%) | 105 (25.1%) | 57 (32.4%) | 0.016 |
Hypertension | 427 (71.8%) | 299 (71.4%) | 128 (72.7%) | 0.07 |
Obesity (BMI > 30 kg/cm2) | 197 (33.1%) | 139 (33.2%) | 58 (32.9%) | 0.58 |
Dyslipidemia | 385 (64.7%) | 275 (65.6%) | 110 (62.5%) | 0.67 |
Preoperative hemoglobin | 13.2 ± 1.8 | 13.3 ± 1.7 | 13.0 ± 1.8 | 0.07 |
Preoperative LVEF | 52.0 ± 13.1 | 54.5 ± 11.8 | 45.7 ± 14.2 | < 0.001 |
Anticoagulation and antiaggregation | ||||
No anticoagulation or antiaggregation | 48 (8.1%) | 36 (8.6%) | 12 (6.8%) | 0.60 |
Acetylsalicylic acid | 498 (83.7%) | 359 (85.7%) | 139 (79.0%) | 0.61 |
ADP receptor inhibitors | 121 (20.3%) | 87 (20.8%) | 34 (19.3%) | 0.96 |
Vitamin K antagonists | 9 (1.5%) | 5 (1.2%) | 4 (2.3%) | 0.28 |
Factor Xa inhibitors | 12 (2.0%) | 6 (1.4%) | 6 (3.4%) | 0.09 |
GPIIb/IIIa inhibitors | 26 (4.4%) | 19 (4.5%) | 7 (4.0%) | 0.87 |
No. of distal anastomoses | 3.4 ± 1.0 | 3.1 ± 0.9 | 3.9 ± 0.9 | < 0.001 |
2 | 127 (21.3%) | 117 (27.9%) | 10 (5.7%) | – |
3 | 221 (37.1%) | 170 (40.6%) | 51 (29.0%) | – |
4 | 168 (28.2%) | 96 (22.9%) | 72 (40.9%) | – |
5 | 70 (11.8%) | 34 (8.1%) | 36 (20.5%) | – |
6 | 9 (1.5%) | 2 (0.5%) | 7 (4.0%) | – |
Crossclamp time (min) | 78.2 ± 27.8 | 79.0 ± 28.9 | 76.2 ± 25.2 | 0.25 |
Composite grafting | 208 (35.0%) | 200 (47.7%) | 8 (4.5%) | < 0.001 |